ERBITUX 2mg / ml solution for infusion medication leaflet

L01FE01 • cetuximab • Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Egfr (epidermal growth factor receptor) inhibitors

Cetuximab is a monoclonal antibody used in the treatment of certain types of cancer, such as metastatic colorectal cancer and head and neck cancer. It works by blocking the epidermal growth factor receptor (EGFR), thereby inhibiting the growth and division of cancer cells.

Cetuximab is administered intravenously and is used either alone or in combination with other therapies, such as chemotherapy or radiation therapy. It is particularly indicated in patients with tumors that do not have KRAS gene mutations, as its effectiveness depends on this genetic factor.

Side effects may include skin reactions (acne-like rash), fatigue, nausea, diarrhea, hypomagnesemia, or severe allergic reactions. It is contraindicated in patients with hypersensitivity to cetuximab or other murine-derived proteins.